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distinguishing benign from malignant adrenal masses in cancer patients.
The study included 33 patients with 39 adrenal masses. CT protocol included pre-contrast scan,
dynamic and delayed contrast-enhanced scans assessing the mass size, pre-contrast attenuation, his-
togram & post-contrast absolute percentage washout (APW). Sensitivities, speciﬁcities, accuracies
& P-values were calculated for individual and combined parameters.
Adrenal masses included 13 lipid rich, nine lipid poor adenomas, one carcinoma and 16 metastases.
Size was accurate in the differentiation of 26 of the total 39 masses (66.7%). Accuracy (82.05%) &
speciﬁcity (68.18%) for the 10% negative pixels threshold on histogram were higher as compared to
76.9% & 59% for the 10 HU mean attenuation threshold. Using APW of 55% at 10 min delay, a
sensitivity of 88.23%, a speciﬁcity of 86.36% & an accuracy of 87.17% were calculated. The24315715, +20 1223571539;
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276 A.M. Mohamed et al.combination of pre-contrast attenuation & histogram values and the APW were highly signiﬁcant
for the differentiation of benign & malignant adrenal masses (P-value is <0.001).
Combining theCTparameters including the pre-contrast attenuation values, histogram& the post-contrast
washout analysis yielded a powerful diagnostic protocolwith 74.3%accuracy, excluding the size parameter.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Adrenal masses––both suspected and incidental––are identiﬁed
at up to 5% of abdominal CT examinations (1). The adrenal
gland is a relatively frequent site for metastatic disease (2).
Adrenal adenomas are present in 4–6% of the general popu-
lation (3). Although most of the adrenal masses turn out to
be adenomas, in a patient with a known history of primary
extra-adrenal neoplasm especially lung carcinoma, this consti-
tutes a major problem. In this setting to diagnose or exclude
an adrenal metastasis is crucial in order to determine a rea-
sonable strategy that requires either follow-up imaging for
adenoma or appropriate therapy of the primary tumor (4).
The presence of metastases may contraindicate curative sur-
gery or radiotherapy (2). The accurate diagnosis of these
masses using CT is important for the staging of malignancies
and for the reduction of the need for both percutaneous
biopsy and follow-up imaging in patients with adrenal masses
(5).
Cross-sectional imaging readily characterizes benign adre-
nal masses, such as lipid-rich adenomas, myelolipomas, adre-
nal cysts, granulomas and adrenal hemorrhage as they have
characteristic diagnostic imaging ﬁndings such as intra-lesional
fat, water or blood. A small minority of adrenal masses eludes
characterization on cross-sectional imaging and remains inde-
terminate. These include lipid-poor adenomas, adrenal metas-
tases, adrenal carcinomas, and pheochromocytomas. For this
group of adrenal masses, the commonest clinical setting is to
differentiate between a benign adrenal adenoma and a malig-
nant lesion, particularly a metastasis (2). Tremendous progress
has been made in the radiological evaluation of adrenal masses
using unenhanced CT and CT contrast washout analysis (6).
The CT histogram analysis is a simple & easily applicable
method which provides higher applicable method of unen-
hanced CT for the diagnosis of an adenoma (4).The two major
predictors of malignancy are the tumor’s size and its imaging
features (7). Kamiyama et al. (5) reported that combining
the diagnostic parameters of the CT protocol can yield the best
diagnostic results.
The aim of this work was to evaluate the effectiveness of
combined CT parameters including the size, pre-contrast
attenuation, histogram & the post-contrast washout analysis
in distinguishing benign from malignant adrenal masses in can-
cer patients than the use of individual parameters.2. Patients & methods
2.1. Patients & masses
This study included 33 patients with known cancer of variable
sites of origin, from the oncology department of Ain ShamsUniversity hospitals. The primary sites of cancer were lung car-
cinoma in 8 patients of whom four had bilateral adrenal
masses, colon carcinoma in ﬁve patients, breast cancer in three
patients, larynx carcinoma in three patients, renal cell carci-
noma in three patients, gastric carcinoma in two patients, testis
carcinoma in two patients, Hodgkin lymphoma in two patients
who had bilateral adrenal masses, prostate cancer tumor in
two patients, primary adrenal cortical carcinoma in one pa-
tient (he was operated upon one year before study & returned
with a recurrent adrenal mass), uterine carcinoma in one pa-
tient, and bladder carcinoma in one patient. The study was
carried over a period of about 24 months. 39 Adrenal masses
were detected with a previous imaging study as a part of a can-
cer workup for staging (six patients had bilateral adrenal
masses).
Patients had undergone the dedicated CT protocol for eval-
uating adrenal masses. All patients were assessed for size sta-
bility at previous and/or follow-up imaging examination by
CT and/or MRI for one year in view of the patients’ history
of cancer. Pathologic proof of diagnosis was obtained in six
patients according to the results of surgical or percutaneous
biopsy specimens.
2.2. Exclusion criteria
 Patients with inadequate follow-up.
 Adrenal cysts (which manifest at CT as water density with
lack of enhancement and an imperceptible wall).
 Pheochromocytoma which were diagnosed on the basis of
their clinical & hormonal ﬁndings).
 Adrenal calciﬁcations or hemorrhage with high CT attenu-
ation values (for not interfering with the pre & post-con-
trast mean attenuation values calculations of the ROI).
2.3. CT scan technique
The CT examinations were preformed by at least eight multi-
detector scanners (GE Healthcare, Milwaukee, WI, USA) with
2.5-slice collimation, 3-mm slice thickness, 1.5 reconstruction
intervals, a kV of 140, 200–300 mA and 0.8-s gantry rotation
time.
Initially, unenhanced images were obtained. IV contrast
(Iopamiro 300; Bracco, Milano, Italy) was given as 100–
150 mL at a rate of 4 mL/s using an automatic pump injector
(Angiomat 6000; Liebel-Flarsheim) via an antecubital vein.
Scanning was initiated 60 s after the start of the injection,
and delayed images were also obtained 10 min later.
The images were sent to the workstation (Hp xw 8600, AW
Volume share 4, GE medical systems SCS, France) where
coronal and sometimes sagittal reformats were reconstructed.
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processing workstation using the commercially available soft-
ware. The image showing the maximal cross-sectional area
was chosen for each adrenal mass where the long-axis and
short-axis diameters were measured. A circular or ovoid region
of interest (ROI) was placed on the adrenal mass including as
much of the mass as possible but excluding the outer edges to
avoid partial volume effects. Approximately half to two-thirds
of each mass was included. The mean attenuation over the
ROI was recorded. The CT histogram was acquired from the
ROI using software application on the workstation where a
graph of the number of pixels on the y-axis versus the pixel
attenuation on the x-axis was obtained from the ROI.
Histogram analysis included recording the total number of
pixels, number of negative pixels with attenuation less than 0
HU, and the resulting percentage of negative pixels in each
ROI.
2.4. Image analysis
Size was recorded with the CT distance cursor to measure the
largest diameter in the axial plane on the unenhanced CT scan.
Masses <4 cm were presumed to be benign while masses
>4 cm were presumed to be malignant.
CT mean attenuation values in Hounsﬁeld units (HU) on
the pre-contrast, contrast-enhanced, and delayed contrast-en-
hanced images were recorded. A threshold value of <10 HU
on the pre-contrast CT scans was chosen for distinguishing be-
nign lesions (e.g. adenomas) from indeterminate lesions
(2,8,9). Similarly, non-calciﬁed, non hemorrhagic lesions with
attenuation values >43 HU were considered malignant (10).
CT histogram: The percentage of each type of adrenal mass
in terms of containing any negative pixel and at the threshold
values of 10% negative pixels on unenhanced CT images wasTable 1 CT features of benign & malignant adrenal masses.
CT parameters Types of lesions
Lipid rich Lipid poor
Size
<4 cm N 9 7
% 69.23 77.78
>4 cm N 4 2
% 30.77 22.22
Pre-contrast attenuation
<10 HU N 13 0
% 100.00 0.00
>10 HU N 0 9
% 0.00 100.00
Pre-contrast histogram
>10% N 13 2
% 100.00 22.22
<10% N 0 7
% 0.00 77.78
APW
>60% N 12 7
% 92.31 77.78
<60% N 1 2
% 7.69 22.22recorded (5). Statistical analysis for correlation between mean
attenuation value and percentage of negative pixels was also
calculated.
The absolute percentage washout (APW) was calculated as
follows:
APW= 100 · ([EADA]/[EAPA]), where EA is attenua-
tion on contrast-enhanced scans, DA is attenuation on delayed
contrast-enhanced scans & PA is pre-contrast attenuation.
Progressive enhancement of a mass on a delayed scan (i.e.,
when attenuation on a delayed scan was greater than attenua-
tion on a dynamic scan) was given a washout score of 0. The
lowest APW threshold values for best discriminating adenoma
were selected (>52% at 10 min post-contrast) (10).
The ﬁnal analysis made use of all the imaging information
from the protocol & was reviewed by two experienced radiol-
ogists; lipid-rich adenomas (which manifest at CT as macro-
scopic fat) were included in the study.
At follow-up imaging, interval growth or appearance of
new lesion was considered to be indicative of malignancy,
while one year of stability was considered to be an evidence
of benignity to be more conservative in those cancer patients’.2.5. Statistical analysis
The recorded data were entered into an Excel worksheet
(Microsoft, Redmond, Wash). Sensitivities, speciﬁcities, posi-
tive predictive values (PPV), negative predictive values
(NPV), and accuracies were calculated for the mass size, the
pre-contrast & post-contrast CT analysis and for the combined
CT parameters used for the differentiation of benign & malig-
nant adrenal masses. The P-values by Chi-square test were also
determined: >0.05 = non-signiﬁcant, <0.05 = signiﬁcant, &
<0.01 = highly signiﬁcant.Chi-square
Malignant Total v2 P-value
7 23 4.106 0.128
41.18 58.97
10 16
58.82 41.03
0 13 39.000 <0.001*
0.00 33.33
17 26
100.00 66.67
0 15 32.428 <0.001*
0.00 38.46
17 24
100.00 61.54
2 21 21.926 <0.001*
11.76 53.85
15 18
88.24 46.15
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Diagram 1 CT features for lipid rich adenomas, lipid poor adenomas, & malignant adrenal masses.
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Thirty-nine adrenal masses were detected in 33 patients (21
men & 12 women; their ages ranged from 26 to 65 years). They
included 13 lipid rich & 9 lipid poor adenomas (22 benign
masses, 56.4%), one adrenal carcinoma and 16 adrenal metas-
tases (17 malignant masses, 43.6%). Characteristic individual
CT imaging features of the adrenal masses including the size,
the pre-contrast mean attenuation & histogram values and
the post-contrast washout analysis (APW)––used for the differ-
entiation of benign & malignant adrenal masses––were summa-
rized in Table 1 & Diagram 1. The sensitivity, speciﬁcity, PPV,
NPV, & accuracy as well as P-values of the individual & com-
bined CT parameters were reported in Table 2 & Diagram 2.
3.1. Individual CT parameters
3.1.1. Size
Sixteen adenomas were <4 cm in maximal diameter (Figs. 1
and 2). Six adenomas were >4 cm in size (6 of 22, 15.38%):
four were lipid rich & had low pre-contrast attenuation values
610 HU, negative pixels on histogram >10, and the other two
were lipid poor and had intermediate attenuation values of 14
& 31HU (>10 HU), one of them had negative pixels on histo-
gram >10%. They all had AWP> 60% & stable size on fol-
low-up imaging.
Ten malignant masses (nine metastatic & one carcinoma,
58.8%) were >4 cm in size (Figs. 3 and 4).Table 2 Statistical assessment of the CT parameters used in differe
CT parameters Sen. Spec. PPV
Size 58.824 72.727 62.500
Pre-contrast attenuation 100.000 59.091 65.385
Pre-contrast histogram 100.000 68.182 70.833
APW 88.235 86.364 83.333
All CT parameters 100.000 36.364 54.839
All excluding the size 100.000 54.545 62.963Seven metastases had small sizes <4 cm (7 out of 17,
17.95%) but their washout was consistent with malignant
behavior (Fig. 5) & three of them had attenuation >43 HU
favoring malignancy. They were proved to be malignant by
histopathology & by increasing size on follow-up imaging.
We concluded that size was accurate in the differentiation
of benign & malignant adrenal masses in 26 of total 39 masses
(66.7%).3.1.2. Pre-contrast mean attenuation values
All the lipid rich adenomas (100%) on unenhanced CT had
low attenuation values 610 HU & P10% negative pixels on
histogram (Fig. 1). The nine lipid poor adenomas (9 of 22 ade-
nomas, 40.9%) had attenuation values >10 HU & <43HU,
(range = 13–32 HU, mean = 21 HU). Two of these lipid poor
adenomas showed P10% negative pixels on histogram &
>60% by AWP favoring benign behavior (Fig. 2). The adre-
nal carcinoma (Fig. 4) & 12 metastases had attenuation >43
HU (Fig. 3), while the rest of malignant cases (4 of 17 malig-
nant masses, 23.5%) had attenuation values ranging from 27
to 41 HU (mean = 33 HU after exclusion of the cases >43
HU) (Fig. 5).3.1.3. Pre-contrast histogram
All lipid rich & two lipid poor adenomas had P10% negative
pixels on histogram (Fig. 1) ranging from 12% to 52%,
mean = 31% (15 of 22 adenomas, 68.18%). Five lipid poorntiation of benign & malignant adrenal masses.
NPV Accuracy Chi-square
v2 P-value
69.565 66.667 4.106 0.128
100.000 76.923 39.000 <0.001*
100.000 82.051 32.428 <0.001*
90.476 87.179 21.926 <0.001*
100.000 64.103 20.129 <0.001*
100.000 74.359 20.129 <0.001*
Diagram 2 Statistical assessment of the CT parameters used in differentiation of benign & malignant adrenal masses.
Fig. 1 Lipid rich adenoma: 47 years old man with a history of cancer colon and right adrenal spherical mass 3 cm in diameter (arrow in
A). The ROI (B) demonstrates 1026 pixels with a median density of 37 HU. The upper and lower limits of pixel attenuation were 53 &
107, respectively. The histogram analysis (C) shows that more than 50% of the mass contains negative pixels. The APW was 77%.
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& only one had <5%.
Only ﬁve of the malignant masses had <5% & the rest did
not show any negative pixels (Figs. 3 and 4).
We obtained 82.05% accuracy & 68.18% speciﬁcity for the
10% negative pixels threshold on histogram as compared to
76.9% accuracy & 59% speciﬁcity for the 10HU mean attenua-
tion threshold value for unenhanced CT scan. Both methods
resulted in 100% sensitivity for the diagnosis of adrenal masses.
Twenty-six masses had low density <10 or high density
>43 HU (66.6%) & only 13 (nine lipid poor & four malignant)
of 39 lesions had intermediate attenuation (33.3%) whichconstitute the main group of the diagnostic challenge. Two
of the lipid poor adenomas showing P10% negative pixels
on histogram were diagnosed to be benign & were excluded
from this group reducing it to 11 masses (28.2%). AWP was
useful for the diagnosis of 8 of these 11 masses (72.72%): 5
of 7 lipid poor masses (71.4%) & 3 of the 4 malignant masses
(75%).
3.1.4. Comparison between the benign & malignant adrenal
masses by their washout criteria (APW)
APW threshold of 55% was accurate in diagnosing 19 benign
masses (ranging from 63% to 85%, mean = 67%, Figs. 1 and
Fig. 2 Lipid poor adenoma: Axial image (A) and coronal reformat (B) of a 26 years old man with a history of orchidectomy for
seminoma. The left adrenal mass (white arrows) was 2.2 cm in diameter. Its median density was 27 HU. The upper and lower limits of
pixel attenuation were 55 & 4, respectively. The histogram analysis shows that 5.4% of the mass contains negative pixels. The APW was
63%.
Fig. 3 Bilateral adrenal metastasis: 50 years old man with bronchogenic carcinoma showing newly developed bilateral adrenal masses A,
B & C are pre-contrast, dynamic, and 10 min delayed scans. The right adrenal mass had a maximum diameter of 12 cm while the left one
measured 2.7 cm in diameter. The right large mass showed a necrotic core which was excluded from the analysis. The two masses had a
median density of 47 and 56 HU, respectively. The upper and lower limits of pixel attenuation were 8 & 76 HU for the left mass. The
histogram analysis did not show any negative pixels. The APW was 27%.
280 A.M. Mohamed et al.2) & 16 malignant masses (ranging from 25% to 47%, Figs. 3
and 5) resulting in a total of 35 from 39 masses (89.74%) as
compared to the cut-off value of 52% which missed the case
of adrenal carcinoma reducing the percentage of diagnosed
malignant masses to 15 cases (total 34 of 39 masses, 87.3%).
By using an APW of 55% at 10 min delay post-contrast, a
sensitivity of 88.23%, a speciﬁcity of 86.36% & an accuracy
of 87.17% were calculated.Two of the lipid poor adenomas were misdiagnosed because
they did not meet the benign criteria of APW & had interme-
diate density & 5–10% negative pixels on histogram. One lipid
rich adenoma showed progressive enhancement getting a score
of 0 but had pre-contrast low attenuation <10HU (5 HU),
negative pixels >10% on histogram. They all had small size
<4 cm & were stable on follow-up imaging. The adrenal car-
cinoma (Fig. 4) showed rapid washout of 55% (>52% but
Fig. 4 Left adrenal carcinoma: 55 years old woman with left adrenal mass (arrowed). (A) The mass measured 7 · 5 cm in its axial
dimensions with a median density of 52 HU, the upper and lower limits of pixel attenuation were 14 & 73 HU, respectively. The histogram
analysis did not show any negative pixels. These ﬁgures are consistent with malignant process; however, The APW was 55%. (B) Follow-
up was done by MRI revealing a considerable increase of the size mass with 9.5 cm at maximal diameter. Excision and biopsy revealed an
adrenal carcinoma.
Fig. 5 Left adrenal metastatic deposit: Coronal reformatted image (A) and axial image with histogram (B) of a 45 years old woman with
a history of cancer breast. The study revealed left adrenal mass 2.5 cm in maximum diameter (arrowed). The median density was 37 HU.
The upper and lower limits of pixel attenuation were 58 & 2, respectively. The histogram analysis shows that only 0.14% of the mass
contains negative pixels. The APW was 33%. Biopsy revealed metastatic disease.
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histopathology. Another adrenal metastasis showed APW
>60%, small size <4 cm & intermediate density (10–43
HU); it was misdiagnosed as benign but was conﬁrmed by his-
topathology to be malignant.
3.2. Value of combined CT parameters
The combined CT parameters succeeded in diagnosing 36
(92.3%) of the total 39 cases (100% of the lipid rich, 77.7%
of lipid poor & 94.1% of malignant masses). They were able
to differentiate benign from malignant masses in 10 of the 13
indeterminate density masses (76.9%). Only 3 of total 39
masses (7.69%) were misdiagnosed: 2 of 9 lipid poor (22.2%)
equivalent to 2 of 22 benign masses (9%) & one metastasis case
(5.8%) of the 17 malignant masses.
The combination of pre-contrast mean attenuation & histo-
gramvalues and the post-contrast washout analysis (APW)were
highly signiﬁcant CT parameters for the differentiation of
benign & malignant adrenal masses (P-value is <0.001). Only
the size parameter was statistically not signiﬁcant as an individ-
ual CT parameter for this differentiation (P= 0.128). The size
had the lowest statistical diagnostic values & the AWP had thehighest values obtained among the studied CT parameters.
The accuracies of combinedCTparameters before& after exclu-
sion of the size parameter were 64.1% & 74.3%, respectively.
3.3. Proof of diagnosis
Pathologic proof of diagnosis was able to conﬁrm malignancy
in six patients (the patient with recurrent adrenal carcinoma &
ﬁve patients with adrenal metastasis: two from lung carci-
noma, two adrenal lymphomas & one from breast cancer).
The three lesions that did not meet the criteria of adenoma
on dedicated adrenal washout study had stable size on follow-
up imaging, and therefore, were presumed to be benign on the
basis of imaging stability. None of the adenomas had increased
in size on follow-up study during the ﬁrst 6 months.
4. Discussion
Characterizing adrenal masses is important because the nature
of the mass may have a profound effect on patient care. Accu-
rate characterization is important for identifying both malig-
nant lesions and benign adenomas because it would obviate
both percutaneous biopsy and repeated interval follow-up
282 A.M. Mohamed et al.imaging. Imaging algorithm for assessing adrenal masses in
which CT plays the predominant role has been proposed (11).
The probability of a speciﬁc type of adrenal mass varies
with the clinical picture. For example, in patients with cancer,
up to 75% of adrenal incidentalomas are metastatic lesions but
in patients with no history of cancer two-thirds are benign
(12). The majority of benign lesions are adenomas, of which
80% are benign non functioning adenomas (2). In the current
study, 39 adrenal masses were diagnosed, of which 56.4% were
benign & 43.6% were malignant.
Considerable overlap in size has been demonstrated be-
tween adenomas and nonadenomas, especially metastases in
previous studies (13,14). In the current study, the size criterion
yielded the lowest sensitivity (58.8%), speciﬁcity (72.7%) &
accuracy (66.6%) as compared to other studied CT parame-
ters. This was comparable to 98% sensitivity & 53% speciﬁcity
in Kamiyama et al. (5) study. The incidence of metastatic adre-
nal lesions increases to 71% if the adrenal mass is larger than
4 cm and demonstrates an increase in size on follow-up imag-
ing within 1 year (15). If the non-contrast CT attenuation va-
lue is greater than 10 HU and the mass measures 6 cm or more,
Gopan et al. (7) suggested referring the patient for surgery.
In agreement with Hamrahian et al. (9) & Gopan et al. (7),
the HU value on non-contrast CT is a better criterion than
tumor size for distinguishing adrenal adenomas from non-ade-
nomas. In the current study, it yielded a higher sensitivity
(100%), speciﬁcity (59%) & accuracy (76.9%) as compared to
the size indices. On non-contrast-enhanced CT, up to 30% of
benign adenomas have an attenuation value of greater than
10 HU and are considered lipid-poor in Pena et al. (13) study
& about 40.9% in the current study. Malignant lesions are also
lipid poor (2). Boland et al. (8) in 1998 performed a meta-anal-
ysis of 10 studies demonstrating that if a threshold attenuation
value of 10 HU was adopted, the speciﬁcity was 98% but the
sensitivity increased to 71%. In clinical practice, therefore, 10
HU is the most widely used threshold attenuation value for
the diagnosis of an adrenal adenoma. In Kamiyama et al. (5)
study, this threshold value yielded 100% accuracy for lipid-rich
adenomas but 57% (30 of 53) sensitivity for total adenomas be-
cause of the 23 lipid-poor adenomas. In the current study, the
same threshold was used with comparable results: 100% sensi-
tivity, 59% speciﬁcity & 76.9% accuracy for the total adrenal
masses & 100% statistical indices for lipid rich adenomas.
In agreement with Blake et al. (10) study, any lesions with
pre-contrast attenuation greater than 43 HU should be
regarded with suspicion (i.e., considered malignant), regardless
of its washout proﬁle. In the current work, thirteen malignant
lesions had pre-contrast attenuation values greater than 43
HU (76.4% of malignant masses), whereas none of the benign
lesions had pre-contrast attenuation values greater than 43 HU.
Also, pre-contrast attenuation of less than 10 HU supersedes
APW in importance. One lipid rich adenoma with pre-contrast
attenuation of less than 10 HU had progressive enhancement
getting an APW value of zero, and one malignancy with pre-
contrast attenuation of greater than 43 HU demonstrated a
marked contrast material washout with an APW value of
55% at 10 min post-contrast.
The use of CT histogram analysis to evaluate adrenal
masses has been proposed by Bae et al. (16). In Halefoglu
et al. (4) study, CT histogram analysis using a 10% negative
pixel threshold has a higher sensitivity than 610 HU mean
attenuation threshold method to discriminate adenomas fromnon-adenomas on unenhanced CT. In the present study, histo-
gram analysis improved the pre-contrast diagnostic accuracy
to 82.05% for the 10% negative pixels threshold as compared
to 76.9% for the 10 HU mean attenuation threshold value for
unenhanced CT scan. Both methods resulted in 100% sensitiv-
ity for the diagnosis of adrenal masses & 100% accuracy for
the diagnosis of lipid rich adenomas. Thus, histogram in
addition to pre-contrast attenuation could distinguish 71.8%
of adrenal masses, being either of low density (lipid rich adeno-
mas) or high density >43 HU (considered malignant until
proved otherwise). Unenhanced CT attenuation could not be
used to sufﬁciently differentiate the intermediate density lipid
poor adenomas from non-adenomas.
Most lipid-poor adenomas can be separated from the
malignant group by recent advances in CT. Lipid-poor adrenal
masses should ﬁrst be evaluated by studying CT contrast med-
ium washout characteristics. Characterization of adrenal
masses using contrast-enhanced CT utilizes the different phys-
iological perfusion patterns of adenomas and metastases.
Attenuation values of adrenal masses obtained 60 s after con-
trast medium injection show too much overlap between adeno-
mas and malignant lesions to be of clinical value. Adrenal
masses with a CT attenuation value measuring less than 30
HU, on delayed images obtained 10 to 15 min after contrast
enhancement, are almost always adenomas (13). However,
the percentage of contrast washout between initial enhance-
ment (at 60 s) and delayed enhancement (at 10 min) can be
used to differentiate adenomas from malignant lesions. These
absolute contrast medium enhancement washout values are
only applicable to relatively homogeneous masses without
large areas of necrosis or hemorrhage. It has been demon-
strated that washout of contrast from adenomas occurs much
faster than from metastases. Both lipid-rich and lipid-poor
adenomas behave similarly, as this property of adenomas is
independent of their lipid content (2). The APW of an adrenal
mass may seem to be a more accurate calculation of de-
enhancement because the pre-contrast attenuation value is in-
cluded in the calculation of APW. APW may be the most use-
ful parameter to differentiate lipid-poor adenomas from non-
adenomas (5).
In this present study, we followed the 10-min delay protocol
which is a more convenient method of adrenal mass character-
ization because it has the inherent advantage of a shorter exam-
ination time as advised by Blake et al. (10) study. The optimal
APW threshold values with the 10-min delay used in their study
were slightly lower than those with a 15 min delay because there
was less time for de-enhancement to occur. The 10-min delay
protocol yielded lower threshold values of 52.0%. Caoili et al.
(14) recommend the use of 60% APW threshold with a 15-min
protocol. On the basis of the results of this current study, in
agreement with Blake et al.(10) study, keeping the same high
threshold for the 10-min protocol––similar to that adopted
for the 15-min protocol––has some merit because it preserves
the desired success in the detection of malignancy (e.g. one
malignant adrenal mass had AWP of 55% & was proved by
biopsy to be metastatic). Delayed enhancement criteria at
5 min may be accurate to differentiate lipid-rich adenomas
from nonadenomas, but they yield lower sensitivity for lipid-
poor adenomas (5). In the current study, an APW of 55% at
10 min delay post-contrast showed the highest sensitivity of
88.23%, speciﬁcity of 86.36% & accuracy of 87.17% as com-
pared to other CT parameters.
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nation of the unenhanced and dynamic enhanced CT protocol
parameters can yield a high diagnostic accuracy in the differen-
tiation of adrenal adenomas from non-adenomas. Combining
the CT parameters studied in the current study yielded a valu-
able diagnostic protocol with an accuracy of 74.3% for distin-
guishing the nature of adrenal masses, considering that size
criterion should not be used as an individual discriminator.
4.1. Limitations
The majority of the adrenal masses was not pathologically
proved and required follow-up imaging for characterization.
This has been an accepted method of classifying benign and
malignant lesions in previous studies (10,13). Size stability dur-
ing a 6-month or longer follow-up to conﬁrm adenomas and
growth of the mass within 6 months or shrinkage after chemo-
therapy to conﬁrm metastases was used in most studies as in
Blake et al. (10), Kamiyama et al. (5), & Halefoglu et al. (4)
studies. Other studies had used one year of stability as a lower
limit (13,14). In the current study, 1 year of stability was used
to be more conservative for the exclusion of adrenal metastasis
as the patients’ population was known with cancer of variable
origins. Yet, none of the adenomas had increased in size on fol-
low-up study during the ﬁrst 6 months & they were presumed to
be benign on the basis of their imaging stability on follow-up.
Therefore, 6 months of follow-up is a sufﬁcient period. No
good evidence supports continuing radiological surveillance if
the ﬁrst follow-up study shows no change in tumor size (7).
In conclusion, non hyper-functioning adrenal masses are
common even in patients with cancer. Most are lipid-rich ade-
nomas and these can be conﬁrmed on a single unenhanced CT
with an attenuation value of less than 10 HU & a histogram
threshold of more than 10% negative pixels. Histogram is
more accurate than pre-contrast attenuation in detecting in-
tra-lesion fat content & is considered a useful tool in diagnos-
ing lipid rich adenomas. The pre-contrast attenuation value of
less than 10 HU supersedes the washout proﬁle in the evalua-
tion of an adrenal mass. Lipid-poor lesions include malignant
adrenal lesions and lipid-poor adenomas. All non-calciﬁed,
non hemorrhagic adrenal lesions with pre-contrast attenuation
of greater than 43 HU should be considered suspicious for
malignancy. After these extreme attenuation limits are consid-
ered, the APW value is an accurate discriminator of the nature
of adrenal masses whether benign or malignant especially for
the intermediate density masses. Size is the lowest CT param-
eter discriminator with considerable overlap between benign &
malignant lesions. Combining the studied CT parameters
yielded a powerful diagnostic protocol in distinguishing benign
from malignant adrenal masses. Six months of size stability is
sufﬁcient to conﬁrm benign adenomas without the need for
further follow-up.Disclosure/Conﬂict of interest
No conﬂict of interest to declare. No Funds, sponsorship or
ﬁnancial support to be disclosed.
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